Compass Therapeutics Q2: Clinical wins drive R&D spend; $101M runway, key readouts in 2026

Compass Therapeutics, Inc. (NASDAQ: CMPX) - Q2 2025 snapshot

Straight to the point: clinical progress is driving higher R&D spending. The company has a solid cash and securities position today but is burning cash faster year‑over‑year. Key trial readouts and program milestones are the main near‑term value drivers.

Key facts & figures (as reported, in thousands unless noted)
* Cash and cash equivalents: $22,856 (June 30, 2025)
* Marketable securities: $78,093
* Cash, cash equivalents and marketable securities (company disclosure): $101 million
* Total current assets: $106,195
* Total assets: $116,698
* Total liabilities: $23,491
* Total stockholders' equity: $93,207 (down from $125,233 at 12/31/2024)
* Accumulated deficit: $(401,197)
* Accounts payable: $2,595; Accrued expenses: $10,992 (project expenses $8,604, including $8.2M accrued manufacturing and $3.6M minimum contractual obligations for CTX‑10726)
* Right‑of‑use (ROU) asset (lease): $9,804; Operating lease obligations, long‑term: $9,633
* Net cash used in operating activities (six months): $(25,040)
* Net change in cash (six months): $(20,627); Cash at beginning of period: $44,051; Cash at end: $23,424 (incl. restricted cash $568)
* Net loss - three months ended June 30, 2025: $(19,881); six months: $(36,514)
* Net loss per share - basic & diluted: Q2 2025 $(0.14); six months $(0.26)
* Weighted average shares outstanding (basic & diluted): 138,282 (Q2 2025)
* Research & development expense - Q2 2025: $16,415 (up from $11,174 YoY); six months: $29,476 (up from $20,695 YoY)
* General & administrative expense - Q2 2025: $4,651 (six months: $9,556)
* Other income (interest): Q2 2025 $1,185 (down from $1,969 YoY); six months $2,518 (down from $3,951 YoY)
* Stock‑based compensation: Q2 2025 $2,791; six months $5,305; remaining unrecognized stock‑based comp: $24.8M

Clinical / operational positives
* Tovecimig (DLL4 x VEGF‑A): Phase 2/3 met primary endpoint (ORR 17.1% vs 5.3% for paclitaxel alone; p=0.031). DMC reviewed safety multiple times and recommended continuation.
* Fewer than expected OS events in the BTC study - company expects pooled OS/PFS analyses in Q1 2026 (could be meaningful if confirmed).
* CTX‑8371 (PD‑1 x PD‑L1): Phase 1 shows deep responses (complete resolution in one NSCLC patient; >90% reduction in one TNBC patient). Cohort expansion planned (NSCLC, TNBC) with data targeted in 2026.
* CTX‑10726 (PD‑1 x VEGF‑A): Preclinical superiority vs competitor in mouse models; IND planned Q4 2025. Using existing components may speed CMC and manufacturing scale‑up.
* Balance sheet: ~$101M in cash + marketable securities and no material debt reported - company states runway into 2027 based on current plans.

Income statement negatives / risks
* Rising R&D spend: R&D cost increased 47% YoY for Q2 (from $11.2M to $16.4M) and 42% for six months - mainly manufacturing and clinical costs for tovecimig and CTX‑10726.
* Widening net loss: Q2 net loss increased to $(19.9M) from $(13.1M) YoY; six‑month loss grew to $(36.5M) from $(23.9M).
* No licensing revenue in 2025 periods (licensing revenue was $850K in prior year periods).
* Interest income declined (reflecting lower cash & securities balances or lower yields), reducing other income contribution.
* Accrued project and manufacturing obligations have jumped (project expenses $8.6M), including contractual minimums tied to development programs - increases near‑term cash demands.
* Accumulated deficit $(401.2M) and declining equity from $125.2M (12/31/24) to $93.2M (6/30/25) underscore cumulative losses and dilution risk if capital is raised.

What matters next
* Pooled OS/PFS analysis for tovecimig expected Q1 2026 - positive results would be a major value inflection.
* CTX‑8371 cohort expansion data (expected 2026) - further clinical signals could support program value.
* IND filing and early data for CTX‑10726 (IND planned Q4 2025, data expected 2026).
* Cash burn and financing plan: company expects runway into 2027 but will likely need to access capital later; timing and terms of any raise will affect dilution and valuation.

Bottom line: Compass is showing meaningful clinical progress (tovecimig primary endpoint and encouraging signals in other programs) that justifies higher near‑term spending. The balance sheet today is adequate into 2027 per management, but rising R&D/manufacturing accruals and widening losses increase the probability the company will need to raise capital before commercialization. Investors should watch the upcoming OS/PFS readout timing (Q1 2026), CTX‑8371 expansion data, and any financing activity.